Home › Trials › NCT07566832
Clinical trial Recruiting at 1 site Interventional Ages 60 to 75

Velocity-based resistance training to reduce inflammation in older adults

Official title: Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

Run by National Taipei University · NCT07566832 · Data updated 2026-11-12

This program will test whether different amounts of velocity-based resistance training can lower inflammation in adults aged 60–75 who do not regularly do resistance exercise.

Quick facts

Study typeInterventional
Ages60 Years to 75 Years
SexAll
Enrollment60 (estimated)
SponsorNational Taipei University
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedApril 20, 2026
Main results expectedMarch 2029
Study endsDecember 2029
Registry record updatedMay 8, 2026
Trial IDNCT07566832 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are otherwise healthy adults aged 60–75 who have not engaged in regular resistance training (≥2 sessions/week) in the past year and can safely perform supervised resistance movements.

Probably not a fit

People with obesity (BMI >30 kg/m²), diabetes, hypertension, cancer, significant heart/kidney/liver disease, regular anti-inflammatory medication use, smoking or alcohol abuse, or inability to perform the exercises safely are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized intervention assigns older adults to low-, medium-, or high-volume velocity-based resistance training or a non-exercise control. Training groups complete a supervised 4-week resistance program emphasizing movement velocity followed by a 4-week detraining phase. Researchers will measure immune and anti-inflammatory markers before training, after training, and after detraining to determine volume-specific effects. The protocol excludes participants with obesity, chronic diseases, regular anti-inflammatory medication use, smoking, or recent musculoskeletal injury to better isolate exercise effects.

Why it matters

Potential benefit: If successful, the results could identify optimal training volumes to lower inflammation and help clinicians prescribe resistance exercise to support healthier aging.

How similar studies have gone: Previous studies have shown resistance training can reduce inflammatory markers in older adults, but velocity-based and volume-specific effects are less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged 60-75 years or older
* No regular resistance training habit (defined as ≥2 sessions per week) in the past year
* No musculoskeletal injuries within the past six months

Exclusion Criteria:

* Obesity (BMI \> 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
* Regular use of anti-inflammatory medications (e.g., NSAIDs).
* Smoking or alcohol abuse
* Inability to safely perform the prescribed resistance exercise movements
* Unable to fully comprehend the study information and instructions.

Where it's running

  • National Taiwan Normal University
    Taipei, Taiwan     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Aging 2413Inflammatory Response 46
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.